Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560481436> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2560481436 abstract "Abstract Background: With the recent reporting of 191 cases of epoetin induced PRCA (Bennett CL, NEJM 2004), information is needed about the long-term follow-up of individuals with this diagnosis. While 47 cases from France, Germany, and England have been reported recently (Verhelst D, Lancet 2004), these data are limited by short follow-up and absence of information from other regions. Methods: RADAR investigators identified cases of epoetin-associated PRCA from the Food and Drug Administration MEDWatch database and proprietary reports from both the manufacturers epoetin alpha (Epogen from AMGEN, and Eprex from Johnson and Johnson) and epoetin beta (Neorecormon from Roche). Patients exposed to more than one epoetin form were excluded. PRCA recovery was operationally defined as transfusion independence, clearance of anti-erythropoietin antibody, and/or normalization of reticulocyte count. Results: See table. Conclusions: The overall recovery rate of 82% following transplantation versus 40% following immunosuppression suggests that transplantation might be the optimal therapy for epoetin-associated PRCA. Almost half of the patients rechallenged with epoetin developed recurrent PRCA, raising concern over the benefits of rechallenge. Eprex (N=82) Neorecormon (N=11) Epogen (N=5) Origin: US 60% 64% 100% Europe 60% 64% – Pacific Rim/Asia 21% 36% – Canada 19% – – Subcutaneous delivery 99% 100% 60% Recovery with Immunosuppression 37% 73% 0% Recovery with renal Transplant 11% – – No recovery with renal transplant 1% – 20% No Recovery 41% 18% 40% Unknown Recovery 10% 9% 40% Male gender 68% 73% 40% Rechallenged with epoetin N=12 – – Response rate 50% Median age 68 years 47 years 51 years" @default.
- W2560481436 created "2016-12-16" @default.
- W2560481436 creator A5001124933 @default.
- W2560481436 creator A5003177689 @default.
- W2560481436 creator A5037145725 @default.
- W2560481436 creator A5037456539 @default.
- W2560481436 creator A5042716202 @default.
- W2560481436 creator A5045928822 @default.
- W2560481436 creator A5063153537 @default.
- W2560481436 creator A5067434226 @default.
- W2560481436 creator A5069161010 @default.
- W2560481436 creator A5071586004 @default.
- W2560481436 creator A5082834438 @default.
- W2560481436 creator A5089700881 @default.
- W2560481436 date "2004-11-16" @default.
- W2560481436 modified "2023-09-29" @default.
- W2560481436 title "Long-Term Follow-Up of 98 Cases of Recombinant Human Erythropoietin (epoetin) Induced Pure Red Cell Aplasia (PRCA): Outcomes and Treatment Data from the Research on Adverse Drug Reactions and Reports (RADAR) Program." @default.
- W2560481436 doi "https://doi.org/10.1182/blood.v104.11.5320.5320" @default.
- W2560481436 hasPublicationYear "2004" @default.
- W2560481436 type Work @default.
- W2560481436 sameAs 2560481436 @default.
- W2560481436 citedByCount "0" @default.
- W2560481436 crossrefType "journal-article" @default.
- W2560481436 hasAuthorship W2560481436A5001124933 @default.
- W2560481436 hasAuthorship W2560481436A5003177689 @default.
- W2560481436 hasAuthorship W2560481436A5037145725 @default.
- W2560481436 hasAuthorship W2560481436A5037456539 @default.
- W2560481436 hasAuthorship W2560481436A5042716202 @default.
- W2560481436 hasAuthorship W2560481436A5045928822 @default.
- W2560481436 hasAuthorship W2560481436A5063153537 @default.
- W2560481436 hasAuthorship W2560481436A5067434226 @default.
- W2560481436 hasAuthorship W2560481436A5069161010 @default.
- W2560481436 hasAuthorship W2560481436A5071586004 @default.
- W2560481436 hasAuthorship W2560481436A5082834438 @default.
- W2560481436 hasAuthorship W2560481436A5089700881 @default.
- W2560481436 hasConcept C126322002 @default.
- W2560481436 hasConcept C2776164570 @default.
- W2560481436 hasConcept C2777422296 @default.
- W2560481436 hasConcept C2778248108 @default.
- W2560481436 hasConcept C2778534260 @default.
- W2560481436 hasConcept C2780252810 @default.
- W2560481436 hasConcept C2911091166 @default.
- W2560481436 hasConcept C71924100 @default.
- W2560481436 hasConceptScore W2560481436C126322002 @default.
- W2560481436 hasConceptScore W2560481436C2776164570 @default.
- W2560481436 hasConceptScore W2560481436C2777422296 @default.
- W2560481436 hasConceptScore W2560481436C2778248108 @default.
- W2560481436 hasConceptScore W2560481436C2778534260 @default.
- W2560481436 hasConceptScore W2560481436C2780252810 @default.
- W2560481436 hasConceptScore W2560481436C2911091166 @default.
- W2560481436 hasConceptScore W2560481436C71924100 @default.
- W2560481436 hasLocation W25604814361 @default.
- W2560481436 hasOpenAccess W2560481436 @default.
- W2560481436 hasPrimaryLocation W25604814361 @default.
- W2560481436 hasRelatedWork W1530777658 @default.
- W2560481436 hasRelatedWork W1985589843 @default.
- W2560481436 hasRelatedWork W1993901273 @default.
- W2560481436 hasRelatedWork W2010005807 @default.
- W2560481436 hasRelatedWork W2012758044 @default.
- W2560481436 hasRelatedWork W2070169917 @default.
- W2560481436 hasRelatedWork W2419120572 @default.
- W2560481436 hasRelatedWork W2427578644 @default.
- W2560481436 hasRelatedWork W3043418333 @default.
- W2560481436 hasRelatedWork W164823710 @default.
- W2560481436 isParatext "false" @default.
- W2560481436 isRetracted "false" @default.
- W2560481436 magId "2560481436" @default.
- W2560481436 workType "article" @default.